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Within a cell or a tissue, molecules’ production, catabolism, 
renewal and turnover rate are strictly controlled by complex 
mechanisms. In the last thirty years, modern molecular biology 
approaches revolutionized genes and proteins characterization, 
with the most relevant improvement for low expressed molecules. 
The signal transduction pathways are actively studied in an 
enormous number of human diseases, including cancer and 
degenerative illnesses. Each human disease might be seen 
as a “signaling disease”. Unfortunately, the causative role in 
diseases’ aetiopathogenesis was demonstrated for a few signal 
transduction molecules. Signal transduction pathways acting 
within a cell overlap. For almost diseases it is not clear the 
impact of a single pathway disruption upon the clinical outcome. 
Indubitably recent knowledge advances in signal transduction 
pathways cascades contribute to elucidate the natural history 
of diseases, with special regard to tumours. Consequently, more 
than considering a single molecule, it might be useful to evaluate 
all the related components of the pathway that molecule belongs 
to. Beside the contribute to knowledge, identification of one or 
more signal transduction pathways alteration in a disease widens 
the number of potential targets. When a single gene is mutated 
causing the disease, studying the molecules which normally would 
interact with the lacking/abnormal protein might allow correct 
the abnormality in the signaling cascade. That might multiply the 
number of elements for diagnosis, prognosis and of targets for 
therapy. All the molecules belonging to a disrupted pathway or to 
a pathway related to an altered gene/protein can be considered. 
That virtually amplifyies the number of target molecules (genes, 
mRNAs and protesins) to upstream and/or downstream, short 
and/or long distance interacting proteins.
Another suggestion of the “signaling disease approach” is 
that the same pathway alteration underlies or contributes 
to clinically different diseases. As other signaling systems, 
inositol phospholipids’ (PI) pathway acts in many functions, 
so that its alteration was involved in diseases which differ for 
aethiopathogenesis and/or clinical epiphenomena, depending 
on brief/long distance interacting and down/upstream 
related molecules. PI related Phospholipase C (PLC) enzymes 
were indicated to be involved in inflammation, tumours, 
neuropsychiatric disorders and single gene diseases. Recent 
evidences indicated that PI-PLC findings can add data about 
the natural history of a disease and clinical outcome. However, 
more investigations will be required in order to purpose them as 
diagnostic or prognostic indicators. 
Interestingly, PI-PLC enzymes, such as many other signaling 
molecules, can be efficiently blocked by specific inhibitors, that 
might indirectly affect the activity of further related molecules. 
Moreover, recent gene silencing-based reports suggested new 
possibilities to regulate the expression of PLC enzymes. Although 
we are far from using our growing knowledge in the field of 
“signaling diseases” for therapy, that also represents a promising 
perspective.
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